APPLICATION OF VILDAGLIPTIN IN COMBINATION WITH INSULIN IN TYPE 2 DIABETES MELLITUS
- Авторлар: Antsiferov M.B.1, Antsiferov MB1
-
Мекемелер:
- Шығарылым: № 3 (2012)
- Беттер: 29-33
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279282
- ID: 279282
Дәйексөз келтіру
Толық мәтін
Аннотация
Currently, the prevalence of type 2 diabetes mellitus (DM2) progressively increases. Along with the progression of diabetes mellitus, need for insulin inevitably arises in connection with the deterioration of β-cell function. Insulin therapy allows to maintain more stringent target levels of blood glucose, but is associated with some side effects, the most serious of which are hypoglycemia and body weight gain. They significantly reduce the quality of life of patients and limit their daily activities. In addition, it was shown that hypoglycemia is independent predictor of high risk of cardiovascular mortality and morbidity. The most difficult problem in the treatment of DM2 patients receiving insulin is the risk of severe hypoglycemia. Therapy based on incretinomimetics, which include dipeptidyl peptidase-4 inhibitors (vildagliptin, etc.), can be considered as pathogenetically substantiated choice for these patients. Drugs of this group are characterized by favorable tolerability and high efficacy, their use is associated with lower risk of hypoglycemia. The results of studies on evaluating the efficacy and safety of vildagliptin added to insulin therapy in DM2 patients are presented.
Негізгі сөздер
Әдебиет тізімі
- UK Prospective Diabetes Study (UKPDS) Group. (UKPDS 33). Lancet 1998;352:837-53.
- ACCORD - the Action to Control Cardiovascular Risk in Diabetes. Am J Cardiol 2007;99:12A.
- Skyler S, Bergenstal R, Bonow R, et al. Intensive Glycemic Control and the Prevension of Cardiovascular Events: Implications of the ACCORD, ADVANCE and VADT. Diabetes Trials Diabetes Care 2009;32(1):187-92.
- ADVANCE Management Committee. Study Rationale and design of ADVANCE. Diabetologia 2001;44:1118-20.
- Sloan FA, Bethel MA, Ruiz D Jr, et al. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med 2008;168(2):192-99.
- Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25(3):245-54.
- Mathieu C, Bollaerts K. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract 2007;154:29-37.
- Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010;70(16):2089-112.
- Fagot-Campagna A, Bourdel-Marchasson I, Simon D. Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care. Diabetes Metab 2005;31(2):5S35-52.
- Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368(9548):1696-705.
- Bourdel Marchasson I, Doucet J, Bauduceau B, et al; ALFEDIAM/SFGG French-Speaking Group for Study of Diabetes in the Elderly. Key priorities in managing glucose control in older people with diabetes. J Nutr Health Aging 2009;13(8):685-91.
- Bourdel-Marchasson I, Berrut G. Caring the elderly diabetic patient with respect to concepts of successful aging and frailty. Diabetes Metab 2005;31(2):5S13-19.
- Abbatecola AM, Paolisso G, Corsonello A, et al. Antidiabetic oral treatment in older people: does frailty matter? Drugs Aging 2009;26(1):53-62.
- V Fonseca A, Schweizern AD, Albrecht MA, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55.
- Marfella R, Barbieri M, Grella R, et al. Vildagliptin and sitagliptin effects on Mean amplitude of glycemic excursions. J Diabet Complic 2009.
- Аметов А.С., Карпова Е.В. Эффективное и безопасное управление сахарным диабетом 2 типа при помощи ингибиторов ДПП-4 // Сахарный диабет 2010. № 2. С. 3.
- Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119(2):351-57.
- Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909.
Қосымша файлдар
